Towaco, NJ, United States of America

Joseph Thomas Rubino

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 130(Granted Patents)


Location History:

  • Towace, NJ (US) (2014)
  • Towaco, NJ (US) (2011 - 2016)

Company Filing History:


Years Active: 2011-2016

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Joseph Thomas Rubino: Innovator in Cytotoxic Drug Conjugates

Introduction

Joseph Thomas Rubino is a notable inventor based in Towaco, NJ (US). He has made significant contributions to the field of cytotoxic drug conjugates, holding a total of 8 patents. His work focuses on developing advanced methods for preparing drug-carrier conjugates that enhance drug loading and reduce aggregation.

Latest Patents

Rubino's latest patents include innovative methods for creating calicheamicin derivative-carrier conjugates. These methods allow for a drug loading that is significantly higher than previously reported procedures, while also minimizing aggregation and achieving a low conjugate fraction (LCF). His patents describe various compositions comprising cytotoxic drug derivative/antibody conjugates, as well as their uses. Notably, he has developed monomeric calicheamicin derivative/anti-CD22 antibody conjugates, which further expand the applications of his research.

Career Highlights

Throughout his career, Rubino has worked with prominent organizations, including Wyeth Holdings Corporation and Wyeth. His experience in these companies has contributed to his expertise in the development of innovative drug delivery systems.

Collaborations

Some of Rubino's notable coworkers include Arthur Kunz and Justin Keith Moran. Their collaboration has likely played a role in advancing the research and development of cytotoxic drug conjugates.

Conclusion

Joseph Thomas Rubino's contributions to the field of cytotoxic drug conjugates demonstrate his innovative spirit and dedication to improving drug delivery methods. His patents and collaborations reflect a commitment to advancing medical science and enhancing therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…